Dandrit Biotech Usa, Inc. (DDRT) SEC Filing 8-K Material Event for the period ending Friday, January 12, 2018

Dandrit Biotech Usa, Inc.

CIK: 1527728 Ticker: DDRT

View differences made from one to another to evaluate Dandrit Biotech Usa, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dandrit Biotech Usa, Inc..


Assess how Dandrit Biotech Usa, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dandrit Biotech Usa, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: DDRT
CIK: 1527728
Form Type: 8-K Corporate News
Accession Number: 0001213900-18-000600
Submitted to the SEC: Wed Jan 17 2018 4:29:06 PM EST
Accepted by the SEC: Wed Jan 17 2018
Period: Friday, January 12, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: